Retinal vein occlusion (RVO) is a prevalent, vision-threatening disease, of which macular edema is a common complication. Standard treatment for RVO-associated macular edema involves intravitreal treatment with anti–vascular endothelial growth factor (anti-VEGF) agents such as ranibizumab, bevacizumab, or aflibercept. Despite success with these agents in clinical trials, anti-VEGF agents may be administered less frequently in clinical practice than in studies.
Retinal vein occlusion (RVO) is a prevalent, vision-threatening disease, of which macular edema is a common complication. Standard treatment for RVO-associated macular edema involves intravitreal treatment with anti—vascular endothelial growth factor (anti-VEGF) agents such as ranibizumab, bevacizumab, or aflibercept. Despite success with these agents in clinical trials, anti-VEGF agents may be administered less frequently in clinical practice than in studies.
Researchers sought to evaluate the efficacy, safety, and injection frequency of anti-VEGF drugs in treating macular edema secondary to RVO in clinical practice, and used a multicenter, retrospective, open-label chart review of 165 patients 18 years and older who received at least 3 intravitreal injections of anti-VEGF from August 2013 to September 2014.
A total of 117 patients had 1 year or more of follow-up after anti-VEGF treatment, and 40 (24.2%) continued to receive anti-VEGF injections and had data available through year 2. Seventeen (10.3%) continued therapy and had data available through year 3.
A total of 1641 anti-VEGF injections were administered, 842 (51.3%) of which were ranibizumab, 724 (41.1%) of which were bevacizumab, and 75 (4.6%) of which were aflibercept. Most patients received repeated injections of 1 agent, but 33.3% (n = 55) of patients switched agents at least 1 time during the study period.
In controlled clinical trials conducted for its approval, ranibizumab was administered monthly for 6 months and as needed through 1 year. By contrast, in this study, patients received a mean of 7.1 (range, 1-15) anti-VEGF injections in year 1, 5.4 (range, 1-13) in year 2, and 5.9 (range, 1-11) in year 3. The mean interval between injections ranged from 1.1 to 1.6 months across the first 16 injections.
The primary end point of combined visual and anatomic response (measured as best-corrected visual acuity of 20/40 or better and central retinal thickness of 250 mcm or less on time-domain optical coherence tomography or 300 mcm or less on spectral-domain optical coherence tomography at the same visit) was achieved by just 20.0% to 36.7% of patients after the first 16 injections.
“In this real-world study, a mean of [5] to [7] anti-VEGF injections was administered yearly, and the response to anti-VEGF therapy was suboptimal in many patients,” write the authors. “More frequent injections may improve outcomes, but some patients do not achieve a dry macula even with monthly injections.”
Reference
Jumper JM, Dugel PU, Chen S, Blinder KJ, Walt JG. Anti-VEGF treatment of macular edema associated with retinal vein occlusion: patterns of use and effectiveness in clinical practice (ECHO study report 2). Clin Ophtalmol. 2018;12:621-629. doi: 10.2147/OPTH.S163859.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
AAM Report: Generics and Biosimilars Savings Reach $445 Billion in 2023, Part 1
September 18th 2024Savings from generic and biosimilar drugs totaled $445 billion in 2023, showing promise for the growth of both markets and highlighting the success of expansion policies for these products, according to a new report from the Association for Accessible Medicines (AAM).
What AmerisourceBergen's Report Reveals About Payers, Biosimilar Pricing Trends
May 28th 2023On this episode of Not So Different, Tasmina Hydery and Brian Biehn from AmerisourceBergen discussed results from a recent survey, that were also presented at Asembia 2023, diving into the payer perspective on biosimilars and current pricing trends across the US biosimilar industry.
Real-World Study Shows Comparable Outcomes Between CT-P13, Remicade in RA
September 14th 2024A real-world study of the biosimilar infliximab-dyyb (CT-P13; Inflectra) in rheumatoid arthritis (RA) reported the majority of patients who initiated CT-P13 switched from the reference product (Remicade) or another biologic or targeted synthetic disease-modifying antirheumatic drug.
Survey of Clinicians: Lower Cost of Biosimilars Is the Main Driver of Treatment Choice in IBD
September 7th 2024Researchers surveyed clinicians from 63 countries and found that adalimumab and infliximab biosimilars, primarily chosen for their lower cost, are widely available and have improved access to biologic treatment in inflammatory bowel disease (IBD).